DaVita Inc. (DVA)

Over the past six months, DaVita's stock has experienced notable movements and analyst attention. In Q4 2025, DaVita announced adjusted EPS of $3.40, surpassing estimates, and revenue increased by 9.9% year-over-year, leading to a 21.2% stock gain. DaVita made a strategic investment in Elara Caring to expand kidney-focused home care, resulting in a 1.7% stock increase. Analyst sentiment has been mixed, with some firms raising price targets due to AI-driven efficiencies and dialysis demand, while Zacks Research downgraded DVA to a "hold". DaVita highlighted progress in value-based kidney care, reporting a 9% improvement in its Total Quality Score and over $200 million in shared savings.

Demand for DaVita's kidney dialysis services is generally steady due to the ongoing treatment required for chronic kidney disease and end-stage renal disease. The aging population and rising rates of chronic conditions continuously fuel the demand for dialysis services. DaVita's management expects a return to 2% annual treatment growth, indicating a consistent, long-term demand trend.

DaVita Inc. is a U.S.-based healthcare company specializing in comprehensive kidney care services for patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD). Its core business is kidney dialysis centers, offering hemodialysis and peritoneal dialysis services in various settings, along with related lab services, integrated kidney care, clinical research, physician services, and transplant software. DaVita focuses on an integrated care model to improve clinical outcomes and quality of life for patients.

DaVita is headquartered in Denver, Colorado, and has a significant operational presence across the U.S., with thousands of outpatient dialysis centers. As of December 31, 2025, it served approximately 295,000 patients across 3,242 outpatient dialysis centers worldwide, including 2,657 in the United States and 585 in 14 other countries. Its international operations extend to regions such as Asia-Pacific, Latin America, and parts of Europe.

DaVita has maintained a positive brand reputation, emphasizing its commitment to patient care, clinical quality, and corporate citizenship. The company has reported reducing hospitalizations, improving mortality rates, and enhancing health access for patients. DaVita has demonstrated continued progress in value-based kidney care models, with positive outcomes in its Kidney Contracting Entities. DaVita published its Community Care report, highlighting achievements in corporate citizenship and progress towards ESG goals. DaVita has been recognized as an employer of choice by various publications.

Institutional investors are the dominant force in DaVita's shareholder base. Major institutional owners include Berkshire Hathaway Inc., Vanguard Group Inc., BlackRock Inc., State Street Corp, and Invesco Ltd. CEO Javier Rodriguez holds approximately 1.1% of the company's shares.